Helmut Brunar

Dr. Helmut Brunar is an executive with vast expertise in the pharma and biotech sector. Before joining as Viravaxx’ CEO, he managed supply chain activities at Johnson & Johnson’s COVID-19 vaccine program. Prior to this, he was CEO & Chairman for 11 years with Axentis Pharma AG where he built a team to develop respiratory drug candidate AX-TOBRA. 

Frank Stolz
Head Clinical & Diagnostics

Dr. Frank Stolz is an experienced head of pre-clinical and clinical product development with a successful history of working in the biotechnology industry and in basic research. At Viravaxx, he is responsible for product innovation, process and analytical development. Frank leads Viravaxx’ preclinical vaccine development and diagnostic platforms.